Neumora Therapeutics (NMRA) Insider Trading & Ownership $10.63 -0.49 (-4.41%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Neumora Therapeutics (NASDAQ:NMRA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage26.40%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$1.39 M Get NMRA Insider Trade Alerts Want to know when executives and insiders are buying or selling Neumora Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NMRA Insider Buying and Selling by Quarter Ad DTI[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it Neumora Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/18/2024Matthew K FustDirectorSell14,049$17.03$239,254.47 10/9/2024Robert A LenzInsiderSell5,563$15.01$83,500.63 9/17/2024Robert A LenzInsiderSell30,788$11.81$363,606.28 8/26/2024Joshua PintoCFOSell31,642$11.78$372,742.76 8/22/2024Joshua PintoCFOSell28,496$11.63$331,408.48 (Data available from 1/1/2013 forward) NMRA Insider Trading Activity - Frequently Asked Questions Who is on Neumora Therapeutics's Insider Roster? The list of insiders at Neumora Therapeutics includes Amgen Inc, Arch Venture Partners Xii, Llc, Henry O Gosebruch, Joshua Pinto, Kristina Burow, Matthew K Fust, and Robert A Lenz. Learn more on insiders at NMRA. What percentage of Neumora Therapeutics stock is owned by insiders? 26.40% of Neumora Therapeutics stock is owned by insiders. Learn more on NMRA's insider holdings. Which Neumora Therapeutics insiders have been buying company stock? The following insiders have purchased NMRA shares in the last 24 months: Amgen Inc ($29,999,985.00), Arch Venture Partners Xii, Llc ($2,626,582.57), Henry O Gosebruch ($189,300.00), and Kristina Burow ($28,803,319.17). How much insider buying is happening at Neumora Therapeutics? Insiders have purchased a total of 3,786,769 NMRA shares in the last 24 months for a total of $61,619,186.74 bought. Which Neumora Therapeutics insiders have been selling company stock? The following insiders have sold NMRA shares in the last 24 months: Joshua Pinto ($704,151.24), Matthew K Fust ($239,254.47), and Robert A Lenz ($447,106.91). How much insider selling is happening at Neumora Therapeutics? Insiders have sold a total of 110,538 Neumora Therapeutics shares in the last 24 months for a total of $1,390,512.62 sold. Neumora Therapeutics Key ExecutivesMr. Paul L. Berns (Age 57)Co-Founder & Executive Chairman Compensation: $1.65MMr. Henry O. Gosebruch (Age 51)President, CEO & Director Compensation: $3.33MMr. Jason G. Duncan (Age 50)Chief Legal Officer Compensation: $315kMr. Robert Lenz M.D. (Age 53)Ph.D., Head of Research & Development Compensation: $770.29kMs. Carol Suh (Age 34)Co-Founder & COO Dr. Robert Michael Poole FACP (Age 67)M.D., Co-Founder & Advisor Dr. Joshua Pinto Ph.D. (Age 39)Chief Financial Officer Compensation: $876.64kMr. Michael Lee MilliganPrincipal Accounting OfficerDr. Rajesh Manchanda Ph.D. (Age 58)Chief Technical Operations Officer Mr. Nicholas Brandon Ph.D. (Age 50)Chief Scientific Officer More Insider Trading Tools from MarketBeat Related Companies Halozyme Therapeutics Insider Trading Krystal Biotech Insider Trading Scholar Rock Insider Trading ADMA Biologics Insider Trading Arcellx Insider Trading Immunovant Insider Trading CRISPR Therapeutics Insider Trading Denali Therapeutics Insider Trading Twist Bioscience Insider Trading Vericel Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:NMRA) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
